Daily Anesthesiology Research Analysis
Analyzed 143 papers and selected 3 impactful papers.
Summary
Analyzed 143 papers and selected 3 impactful articles.
Selected Articles
1. Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial.
In this single-masked randomized trial (interim n=60), holding one dose of GLP-1/GIP agonists before elective upper endoscopy significantly reduced clinically significant residual gastric volume versus continuing therapy, meeting an early stopping boundary. The absolute risk difference was 21.9% overall, with the greatest effect in EGD-only cases; clear liquids the day prior mitigated risk in combined EGD+colonoscopy.
Impact: This trial directly informs peri-endoscopic anesthesia/sedation risk management for the rapidly expanding population using GLP-1/GIP agonists, with immediate practice implications.
Clinical Implications: For elective upper endoscopy under moderate sedation/MAC, advise holding one dose of weekly/daily GLP-1/GIP agonists when feasible, especially for EGD-only cases; consider a clear-liquid day prior to mitigate risk if combining with colonoscopy.
Key Findings
- Clinically significant residual gastric volume occurred in 3.1% (hold) vs 25.0% (continue); absolute difference 21.9% (90% CI, 7.0%-36.7%; P=.003).
- EGD-only subgroup: 5.0% (hold) vs 46.7% (continue); absolute difference 41.7% (P=.001).
- No clinically significant RGV events in EGD+colonoscopy patients on clear liquids the day prior.
- Trial was stopped early per O’Brien-Fleming boundary due to excess risk in the continue arm.
Methodological Strengths
- Randomized, single-masked design with prespecified noninferiority/safety boundary and early stopping rule
- Clinically meaningful composite endpoint tied to airway safety and procedural outcomes
Limitations
- Interim analysis with small sample size (n=60) and early termination may overestimate effect size
- Single-masked design and two-center setting may limit generalizability
Future Directions: Confirm findings in larger, multicenter trials across procedure types and anesthesia depths; define standardized fasting/clear-liquid protocols and medication-hold intervals by agent half-life.
IMPORTANCE: Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are known to increase the risk of retained gastric contents. High-quality data are lacking to guide periprocedure management of GLP-1 and GIP agonists. OBJECTIVE: To compare the risk of clinically significant residual gastric volume (RGV) in patients who continue vs hold 1 dose of weekly or daily GLP-1 and GIP agonists prior to sedation. DESIGN, SETTING, AND PARTICIPANTS: This randomized, single-masked clinical trial conducted at 2 large tertiary referral centers in the US included patients undergoing elective upper endoscopy (EGD) who were receiving GLP-1 or GLP-1/GIP agonists between July 2024 and May 2025. Eligible participants were adults aged 18 years or older, scheduled for EGD with or without colonoscopy, under moderate sedation or monitored anesthesia care, and taking a stable dose of a GLP-1 or GLP-1/GIP agonist for at least 1 month. Exclusion criteria were prior foregut surgery, achalasia, documented gastroparesis, RGV on previous endoscopy, gastric outlet obstruction, planned general anesthesia, or recent opioid use. Data were analyzed May 2025. INTERVENTION: Participants were randomized to either continue their medication or hold 1 dose prior to the procedure. MAIN OUTCOMES AND MEASURES: Clinically significant RGV, a composite of gastric contents that (1) precludes endoscopic examination, (2) requires premature termination or endotracheal intubation, and/or (3) results in an aspiration event that necessitates extended observation or monitoring, unplanned therapeutics, or hospital admission.
2. Auricular Vagus Nerve Stimulation Reduces Postoperative Delirium After Major Non-Cardiac Surgery in Elderly Patients.
In a randomized trial of 150 older adults undergoing major non-cardiac surgery, active taVNS reduced postoperative delirium from 25.3% (sham) to 12% (RR 0.47; 95% CI 0.23–0.98). Improved postoperative sleep quality was observed, suggesting a plausible mechanistic link via autonomic modulation and sleep enhancement.
Impact: Provides a nonpharmacologic, scalable, and intraoperatively deliverable strategy to prevent postoperative delirium in a high-risk population.
Clinical Implications: Consider taVNS intraoperatively in older adults at risk for delirium when resources and expertise allow; integrate with multimodal delirium-prevention bundles focusing on sleep and autonomic stability.
Key Findings
- POD incidence: 12% with active taVNS vs 25.3% with sham (RR 0.47; 95% CI 0.23–0.98).
- Stimulation protocol: started 5 minutes before induction and continued through surgery; only site differed (cymba conchae vs earlobe).
- Postoperative sleep quality improved in the active taVNS group, suggesting a mediating pathway.
Methodological Strengths
- Randomized sham-controlled design with clear primary outcome
- Standardized stimulation timing and intraoperative delivery
Limitations
- Single-trial sample size (n=150) with potential center-specific effects
- Blinding integrity may be challenged by sensation differences at stimulation sites
Future Directions: Replicate in multicenter settings, compare dosing parameters, and evaluate integration into ERAS/geriatric pathways with cost-effectiveness and implementation outcomes.
BACKGROUND: Postoperative delirium (POD) is a prevalent and devastating complication in elderly patients undergoing major surgery, marked by substantial increases in morbidity, mortality, and long-term cognitive decline. However, treatment and prevention methods are limited. Accumulating evidence suggests that vagus nerve stimulation effectively enhances cognitive function. OBJECTIVE: To evaluate the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) on POD in elderly patients undergoing major non-cardiac surgery. METHODS: Patients aged ≥65 years scheduled for major non-cardiac surgery were randomly assigned to either the active taVNS group or the sham taVNS group, with stimulation targeting the cymba conchae or earlobe, respectively. In both groups, stimulation was initiated 5 minutes prior to anesthesia induction and continued until the end of surgery. The only difference between the two groups was the stimulation site. The primary outcome was the incidence of POD during the first 3 postoperative days.
3. Pathogen characteristics are key determinants of distinct host response phenotypes of sepsis.
Across 8,280 ICU sepsis cases, pathogen identity, burden, virulence, and infection site independently mapped to hyper- vs hypoinflammatory phenotypes; gram-negative Enterobacterales infections tracked strongly with hyperinflammatory states. Murine/swine models recapitulated these relationships, and phenotype modified prognostic utility (e.g., lactate clearance) and response signals in a trial secondary analysis.
Impact: This study reframes sepsis heterogeneity by elevating pathogen features as primary determinants, providing testable axes for phenotype-aware diagnostics, prognostication, and targeted interventions.
Clinical Implications: In anesthesiology-led critical care, incorporate pathogen identity and burden into early risk stratification and trial design; phenotype-aware endpoints (e.g., lactate clearance) and endotoxin-targeted strategies may require selection by inflammatory class.
Key Findings
- Pathogen identity (notably gram-negative Enterobacterales), burden, virulence, and site independently associated with hyperinflammatory sepsis.
- Controlled murine and swine models confirmed pathogen-driven shifts toward hyperinflammatory biology.
- Prognostic value of lactate clearance varied by phenotype; in EUPHRATES secondary analysis, hypoinflammatory patients had worse survival with endotoxin hemoadsorption.
Methodological Strengths
- Large multicohort clinical analysis integrated with controlled murine and swine models
- Independent validation via secondary analysis of an RCT (EUPHRATES)
Limitations
- Primary human data are retrospective and subject to residual confounding
- Phenotype classification and biomarker availability may vary across centers
Future Directions: Prospective, pathogen-informed enrichment strategies in sepsis trials; deploy rapid diagnostics to pair organism features with phenotype-adapted therapies.
BACKGROUNDSepsis encompasses considerable biological and clinical heterogeneity. Previously, 2 phenotypes ("hyperinflammatory" and "hypoinflammatory") have been consistently identified within sepsis via latent class analysis. These phenotypes differ in their biological features, clinical outcomes, and therapeutic responses to interventions. Prior studies of sepsis heterogeneity have focused primarily on the host response. Here, we investigate the potential influence of the causative pathogen on sepsis heterogeneity and pathobiology.METHODSWe performed a retrospective observational analysis of 8,280 critically ill patients with sepsis to identify associations between pathogen characteristics and the hyperinflammatory and hypoinflammatory patient phenotypes. We also performed controlled murine and swine modeling of sepsis and lung injury and a secondary analysis of 449 patients enrolled in the EUPHRATES randomized controlled trial.RESULTSPathogen characteristics (pathogen identity, burden, virulence, and anatomic site of infection) were strongly and independently associated with the previously reported phenotypes. In a cohort of critically ill patients with sepsis, infection with gram-negative pathogens, primarily Enterobacterales spp. (e.g., Escherichia coli, Klebsiella pneumoniae), was strongly associated with the hyperinflammatory phenotype. The hyperinflammatory phenotype was also independently associated with increased pathogen burden, virulence, and initial anatomic site of infection. In controlled murine and swine modeling, both the identity and burden of the pathogen provoked key biological features of the hyperinflammatory phenotype. Among patients with sepsis, the prognostic value of lactate clearance varied substantially by phenotype. In a secondary analysis of a randomized trial of polymyxin B hemoadsorption (which removes circulating endotoxin), hypoinflammatory patients experienced worse survival.CONCLUSIONSOur results demonstrate the central importance of pathogen features in the clinical and biological heterogeneity of sepsis. Future studies of sepsis pathobiology and heterogeneity should expand their scope beyond the host response, as understanding pathogen-host interactions will be crucial in the development of precision therapeutic strategies to improve patient outcomes.TRIAL REGISTRATIONEUPHRATES trial NCT01046669.FUNDING5P30AG024824, IK2CX002766, R01HL144599, K24HL159247, R01HL158626, R01HL173531, R35GM142992, R35GM145330, R35GM136312, K23HL166880, R35HL140026.